- Home
- ESGL vs SKYE Comparison
ESGL vs SKYE Comparison
Compare ESGL & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ESGL | SKYE |
|---|---|---|
| Founded | 1999 | 2012 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 165.3M | 44.9M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ESGL | SKYE |
|---|---|---|
| Price | $4.00 | $1.12 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $14.75 |
| AVG Volume (30 Days) | 7.4K | ★ 244.8K |
| Earning Date | 12-26-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,328,277.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.90 | $1.09 |
| 52 Week High | $4.32 | $5.75 |
Technical Indicators
Market Signals| Indicator | ESGL | SKYE |
|---|---|---|
| Relative Strength Index (RSI) | 65.13 | 34.37 |
| Support Level | $3.80 | $1.10 |
| Resistance Level | $3.95 | $1.27 |
| Average True Range (ATR) | 0.15 | 0.09 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 100.00 | 0.00 |
Price Performance
Historical ComparisonAbout ESGL ESGL Holdings Limited
ESGL Holdings Ltd is a waste management, treatment, and recycling company involved in the collection and recycling of hazardous and non-hazardous industrial waste from customers such as pharmaceutical, semiconductor, petrochemical, and electroplating companies.
About SKYE Skye Bioscience Inc.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.